<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908336</url>
  </required_header>
  <id_info>
    <org_study_id>ML25033</org_study_id>
    <nct_id>NCT00908336</nct_id>
  </id_info>
  <brief_title>Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen</brief_title>
  <official_title>Phase II, Multicenter, Randomized, Open Label Study of a Sequential Treatment of Intermittent Erlotinib and Docetaxel Versus Erlotinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer After Failure of a Prior Chemotherapy Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Arnau de Vilanova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Arnau de Vilanova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erlotinib has demonstrated efficacy as a single agent in patients with NSCLC and the addition
      of erlotinib to chemotherapy has not achieved better results in the general population.

      However, several preclinical and phase I studies have shown that a sequential treatment of
      erlotinib and chemotherapy could avoid a possible negative interaction between both drugs
      when administrated concomitantly, and therefore, it could improve the benefit of the
      combination therapy.

      This study will investigate if the intermittent treatment of a chemotherapy drug, such as
      docetaxel, with erlotinib could achieve a clinical benefit.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients without disease progression after 6 months of treatment.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from randomization until objective tumor progression or death for any cause. Tumour progression will be assessed every 2 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>The time from the first complete response or partial response until objective tumor progression or death due to progression disease. Tumour progression will be assessed every 2 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>The proportion of patients with tumor size reduction (complete response or partial response following RECIST criteria). Response will be assessed every 2 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>The proportion of patients without tumor size increase (complete response, partial response or stable disease following RECIST criteria). Response wil be assessed every 2 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from randomization until death from any cause. Follow up wil be assessed every 3 months after finishing study treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>Toxicity will be discribed per cycle and per patient according to CTCAE vs. 3, every 3 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel and Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental arm will receive sequential treatment of intermittent erlotinib and docetaxel up to 4 cycles in the absence of disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.
After 4 cycles, participants will receive 150 mg of erlotinib per day until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erlotinib (Tarceva®) 150 mg/day po daily until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel and Erlotinib</intervention_name>
    <description>Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression</description>
    <arm_group_label>Docetaxel and Erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150 mg/day po daily</description>
    <arm_group_label>Erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Age &gt;= 18 years.

          -  Histologically or cytologically documented inoperable, locally advanced (stage IIIb
             with malignant pleural or pericardial effusion) or metastatic (Stage IV) NSCLC.

          -  Patients who have failed only one prior chemotherapy to treat the advanced disease and
             candidates to receive a second line treatment.

          -  ECOG PS 0-2.

          -  Adequate hematological function: hemoglobin =&gt; 9 g/dl; neutrophils count =&gt; 1.5 x
             10(9)/l; platelet count =&gt; 100 x 10(9)/l.

          -  Adequate liver function: Bilirubin &lt;= 1,5 x ULN; AST and ALT &lt;= x 3 ULN when no
             hepatic metastases or &lt;=5 x ULN if hepatic metastases; Alkaline phosphatase &lt;=5 x UNL
             except that there is hepatic metastases.

          -  Adequate renal function: Calculated creatinine clearance =&gt; 40 mL/min (Cockroft y
             Gault) or serum creatinine &lt;= 1.5 x ULN .

          -  Patient able to meet the requirements of the study and accessible for correct
             follow-up.

          -  Oral swallowing capability.

        Exclusion Criteria:

          -  Previous treated with more than one chemotherapeutic treatment for NSCLC

          -  Concomitant treatment with another drug under investigation.

          -  Pregnancy or lactation. Fertile women must provide a negative result of pregnancy test
             (in serum or urine) within 7 days prior to study treatment start. In addition, they
             must use an effective method of contraception (oral contraceptives, intrauterine
             device, barrier methods of contraception, together with spermicidal jelly or surgical
             sterilization) during the study.

          -  Evidence of other disease, metabolic or neurological dysfunction, physical examination
             finding, or clinical laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicates use of an investigational drug or patient at high risk
             from treatment complications.

          -  Contraindication for the use of erlotinib or docetaxel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Juan, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaspar Esquerdo, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínica de Benidorm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Sánchez, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Provincial de Castellón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Maciá, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de Elda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Giner, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Sagunto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Muñoz, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Universitario Dr. Peset</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio López, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Juan de Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Aparisi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de los Lirios</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oscar Juan, Doctor</last_name>
    <phone>0034963868501</phone>
    <email>juan_osc@gva.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vicente Alberola, Doctor</last_name>
    <phone>0034649974055</phone>
    <email>alberola_vicara@gva.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Virgen de los Lirios</name>
      <address>
        <city>Alcoy</city>
        <state>Alicante</state>
        <zip>3804</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Aparisi, Doctor</last_name>
      <phone>0034966528804</phone>
      <email>joseponcelorenzo@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Aparisi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínica de Benidorm</name>
      <address>
        <city>Benidorm</city>
        <state>Alicante</state>
        <zip>03501</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaspar Esquerdo, Doctor</last_name>
      <phone>0034965853850</phone>
      <email>gesquerdo@clinicabenidorm.com</email>
    </contact>
    <investigator>
      <last_name>Gaspar Esquerdo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Elda</name>
      <address>
        <city>Elda</city>
        <state>Alicante</state>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonia Maciá, Doctor</last_name>
      <phone>0034966989109</phone>
      <email>smacia@tiscali.es</email>
    </contact>
    <investigator>
      <last_name>Sonia Maciá, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castellón de la Plana</city>
        <state>Castellón</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfreso Sánchez, Doctor</last_name>
      <phone>0034964354350</phone>
      <email>asanchezh@seom.org</email>
    </contact>
    <investigator>
      <last_name>Alfredo Sánchez, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Giner, Doctor</last_name>
      <phone>0034962659405</phone>
      <email>vginermaco@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Vicente Giner, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio López, Doctor</last_name>
      <phone>0034965938639</phone>
      <email>aljimenez73@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio López, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Juan, Doctor</last_name>
      <phone>0034963868500</phone>
      <email>juan_osc@gva.es</email>
    </contact>
    <investigator>
      <last_name>Oscar Juan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Muñoz, Doctor</last_name>
      <phone>0034961262300</phone>
      <email>munyoz_joslan@gva.es</email>
    </contact>
    <investigator>
      <last_name>José Muñoz, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>May 22, 2009</last_update_submitted>
  <last_update_submitted_qc>May 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vicente Alberola Candel</name_title>
    <organization>ASOCIACIÓN TERAPEUTICA EN HEMATOLOGÍA Y ONCOLOGÍA MÉDICAS H. ARNAU DE VILANOVA</organization>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Carcinoma, Non-Small Cell</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

